Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic. Issue 9 (19th May 2020)

• Record Type: Journal Article
• Authors: Chen, Chun-Fan; Chen, Yung-Tai; Chen, Tz-Heng; Chen, Fan-Yu; Yang, Yi-Ping; Wang, Mong-Lien; Huo, Teh-Ia; Chang, Yuh-Lih; Charis Tan, Ann; Lin, Chih-Ching
• Is Part Of: Journal of the Chinese Medical Association. Volume 83:Issue 9(2020)
• Page Start: 809
• Page End: 811
• Publication Date: 2020-05-19
• Subjects: Angiotensin-converting enzyme -- Coronavirus infection 2019 (COVID-19) -- Sodium glucose cotransporter-2 inhibitors; Medicine -- Periodicals; 610.5
• DOI: 10.1097/JCMA.0000000000000354
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : Sodium glucose cotransporter-2 inhibitors (SGLT2i), a novel antidiabetic drug blocks the reabsorption of glucose in proximal tubules of kidney, are demonstrated to have cardiovascular and renal benefits for people with diabetes. The benefits are associated with the significant increase of intrarenal angiotensin-converting enzyme II (ACE2) expression and blood volume contraction. However, the increased ACE2 may be detrimental to patients infected with the coronavirus infection 2019 (COVID-19), which is found to invade cells via the entry receptor of ACE2. Besides, an SGLT2i-induced natriuretic effect may also increase the risk of acute kidney injury and affect the hemodynamic stability during systemic infection disease. In this article, we explain the mechanisms why the use of SGLT2i in people with diabetes may lead to worse outcomes and suggest clinician to judiciously use it during COVID-19 pandemic.